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Introduction: Administration of human C1 esterase inhibitor (Berinert® P) from target import is the most widespread
treatment strategy for patients with hereditary angioedema (HAE). However, a therapeutic health program includ-
ing Ruconest® (conestat alfa) could shorten a patient’s expectancy for a life-saving treatment.
Aim: To evaluate the cost-utility of Ruconest® (conestat alfa) financed from public funds within the newly introduced
therapeutic health program compared with Berinert® P (human C1 esterase inhibitor) in the treatment of acute angioede-
ma attacks in adults with HAE.
Material and methods: The cost-utility analysis from the Polish healthcare payer’s perspective was performed for
1 year (2012). The costs and health outcomes were simulated for three pairs of eligible HAE patient groups (active
treatment and corresponding placebo). The incremental costs of each intervention compared with placebo were list-
ed together (direct or indirect comparisons between options were impossible due to limited clinical data available).
Results: The incremental cost-utility ratios (ICURs) for the evaluated interventions compared with placebo were as
follows: EUR 15,226 per QALY (Ruconest®) and EUR 27,786 per QALY (Berinert® P). The probability of cost-utility (ICUR
< EUR 24,279 per QALY) assessed for Ruconest® administered in the case of acute angioedema attack was 61% and
41% for Berinert® P.
Conclusions: The administration of Ruconest® in acute life-threatening angioedema attacks is economically justi-
fied from the Polish healthcare payer’s perspective, results in lower costs and is characterized by higher cost-utili-
ty probability compared with Berinert® P.
Key words: acute angioedema attacks, conestat alfa, cost-utility analysis, hereditary angioedema, human C1 esterase
inhibitor.
Introduction
Hereditary angioedema (HAE) caused by C1-esterase
inhibitor deficiency is an autosomal-dominant disease,
although 25% of cases can occur as a result of de novo muta-
tions [1]. Hereditary angioedema is characterized by recur-
rent attacks of intense, massive, localized subcutaneous ede-
ma (involving the extremities, genitalia, face or trunk) or
submucosal edema (of the upper airway or bowels) [2, 3].
Most HAE patients have either a quantitative (type I) or func-
tional (type II) defect in the C1 inhibitor (C1-INH). Type III,
which is characterized by normal quantitative and functional
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C1-INH levels and estrogen dependence, occurs more fre-
quently in females [4]. Studies based on national HAE reg-
istries show a minimal prevalence ranging from 1.09 to 1.51
in 100,000 inhabitants [5-7]. Estimates indicate that ap prox-
imately 1 in 50,000 people in the general population has HAE
[8]. The number of Polish patients with hereditary angioede-
ma (HAE) was assessed at 242 cases (including children and
adults) on the basis of the registry of the Polish Aid Asso-
ciation for Patients with Hereditary Angioedema [4]. In addi-
tion, some sources indicate that the Polish HAE population
could reach even 500-700 patients [4]. The problem is that
there are a lot of patients who did not suffer an angioede-
ma attack strong enough for HAE diagnosis or the disease
symptoms were wrongly recognized. 
Over the last decade, the management of HAE has been
dramatically changing. Numerous C1-INH replacement
options are used. Human C1-INH is a plasma serine protease
inhibitor that inhibits proteases in the coagulation/fibrinolytic
system, the complement system, and the kinin system [9].
Conestat alfa (Ruconest®), recombinant human com-
plement component 1 (C1) esterase inhibitor (rhC1INH), is
an analogue of human C1-INH and is obtained from the milk
of rabbits expressing the gene encoding for human C1-INH.
The amino acid sequence of conestat alfa is identical to that
of endogenous C1-INH. Inhibition kinetics was found to be
comparable with those observed for plasma-derived
human C1-INH [10].
In the actual clinical practice in Poland [11-13], the admin-
istration of the human C1 esterase inhibitor (Berinert® P)
is the most widespread strategy. It can be used in the frame-
work of target import procedure as well as fresh frozen plas-
ma (FFP) in single cases but it is a very inconvenient and
time-consuming procedure (those medical products are reim-
bursed on the basis of individual patient’s application and
the number of vials is limited). In terms of the current sit-
uation, an introduction of the new therapeutic health pro-
gram including reimbursed C1 esterase inhibitor (Rucon-
est®) could shorten a patient’s expectancy for a life-saving
treatment. The inclusion criteria of the mentioned thera-
peutic health program should include acute angioedema
attacks in adults with diagnosed C1 esterase inhibitor defi-
ciency (types I and II) while patients ought to be excluded
in the case of known or suspected allergy to rabbits or hyper-
sensitivity to the active substance (conestat alfa) or to any
of the excipients.
In this paper we evaluate the cost-utility of Ruconest®
(conestat alfa) compared with Berinert® P (the human C1
esterase inhibitor) in the treatment of acute angioedema
attacks in adults with HAE due to C1 esterase inhibitor defi-
ciency in a Polish setting.
Material and methods
Cost-utility analysis
The disease model was designed to calculate the
costs and effects associated with the treatment of acute
angioedema attacks in adults with HAE. The effects were
expressed in non-monetary units, such as life years gained
(LYG) or quality adjusted life years gained (QALYG). The final
results were expressed as the incremental cost-utility
ratio (ICUR), which is defined as the ratio of the difference
in costs to the difference in effects between the active treat-
ment and corresponding placebo: ICUR = (Ca – Cb)/(Ea – Eb),
where Ci is the cost and Ei is the effect of an intervention
(a or b) [14]. The cost-utility of the therapy was assumed
when the ICUR was lower than EUR 24,279 (PLN 99,543) per
QALY, which is set as threshold acceptability in Poland (tripled
GDP per capita) [15].
Population
The population consisted of HAE patients with C1-
esterase inhibitor deficiency with the risk of an acute
angioedema attack. The model simulated two cohorts of
eligible patients treated with one of the following: cones-
tat alfa (50 U/kg) or human C1-INH (20 U/kg) and two cor-
responding cohorts of HAE patients without any active treat-
ment (equivalent to placebo). In all of the above cohorts,
patient characteristics (in each simulation) were the same
(the course of angioedema attack treated with compared
drugs was simulated in identical populations). Patients were
observed between and during angioedema attacks. 
Discrete event simulation model
Discrete event simulation (DES) is one way of observ-
ing the time-dependent (or dynamic) behavior of a system
[16]. It was proposed as a computational tool for cost effec-
tiveness analyses and the key principles of the method were
reiterated: entities, events and time [17]. Entities are the
items that evolve through the simulation – and in the clin-
ical models these are usually patients who are assigned
attributes (e.g. age, sex, duration of the disease) with a spe-
cific value (distribution) each. These values are defined at
the start of the simulation and may be updated as re quired:
age increases, disease severity levels rise and fall, etc. Oth-
er model specifications such as time horizon and discount
rate are encoded in variables and they may change during
the simulation. An event is defined as anything that can hap-
pen during the simulation. This can include occurrence of
a period without attacks, acute attack, life-threatening attack
and death, etc. The events can change the course of a giv-
en patient’s experience by influencing that patient’s attri -
butes and the occurrence of future events. The rates at which
events occur can take on any functional distribution sup-
ported by the data. They can be dependent on any attrib-
utes or variables and these functions can change over time
as appropriate. The third fundamental component of
a DES is time itself. An explicit simulation clock keeps track
of the passage of time [17, 18]. 
The brief model scheme using discrete event simula-
tion is presented in Figure 1 and main model parameters
are shown in Table 1. Time horizon was set at one year, which
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Table 1. List of the parameters used as a model input
Model parameters Value* Comment
Product price Ruconest® EUR 1,174.76 (PLN 4,816.52) The product is not available in Poland
Product price Berinert® P EUR 932.52 (PLN 4,029.29) The product is financed by the public  
payer within the target import procedure
– as a life saving drug
Average patient body weight 76.95 kg
Mode of drug administration Outpatient procedure: 80%
– Ruconest®, Berinert® P, hospitalization < 2 days: 10%
hospitalization for > 1 day: 10%
Cost of inpatient and outpatient Ruconest®: EUR 60.24 (PLN 247.0),
care (per acute attack of Berinert® P: EUR 91.51 (PLN 357.20)
angioedema)
Cost of diagnostics (annually) Ruconest®: EUR 90.92 (PLN 372.78) Min: EUR 68.19 (PLN 279.59)
Berinert® P: diagnostic tests are carried out in the Max: EUR 124.39 (PLN 510.0)
framework of inpatient and outpatient services 
related to the administration of drugs in the treat-
ment of acute life-threatening angioedema 
attack
Death risk in placebo cohorts 30%
Life-threatening acute attacks 5%
Percentages of patients in the High risk: 40.7%
target population divided by risk Moderate risk: 49.7%
of an acute attack Low risk: 5.0%
Absence of seizures: 4.6%
Number of acute attacks per year High risk: 13.0 From minimum to maximum: high risk:
per patient according to risk groups Moderate risk: 8.5 12 to 14, moderate risk from 6 to 11, 
of an acute attack Low risk: 3.0 low risk: 1 to 5
Absence: 0.0
The life quality of a patient between 0.9 Average life quality of patients from the
angioedema attacks general population
The life quality of a patient at the 0.315 Based on severity of the symptoms
maximum intensity of attack
Willingness to pay (WTP) EUR 24,278.78 (PLN 99,543.00) Assuming tripled GDP per capita cost-
utility threshold [18]
*Assuming that EUR 1 = PLN 4.10
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seemed to be a reasonable compromise between the short
clinical trials observation time and the median life expectan-
cy horizon. The patient’s observation during the period
between attacks was performed with 1-day accuracy and
during the acute, life-threatening attack was monitored with
1-hour precision. The simulation was performed for all
patients from the estimated population and repeated 1,000
times while cost and efficacy parameters were randomized
in accordance with their probability distributions. Firstly, the
model counted average costs (average total cost and
average cost parameters) and health outcomes (quality-
adjusted life years) per patient, assuming all parameters
were constant (except for patient characteristics) and after
that the average annual costs and health effects were sum-
marized considering all model parameters as variable (ac -
cording to assumed probability distributions).
Clinical data
The clinical data input is based on the systematic search
of medical databases [19] performed by two analysts work-
ing independently and conducted according to the Evidence
Based Medicine standards [20], Cochrane Collaboration [21]
and Polish Health Technology Assessment Agency (Agen -
cja Oceny Technologii Medycznych; AOTM) Guidelines
[22] that yielded two placebo-controlled studies for cone-
stat alfa (Ruconest®) [23, 24] and two for human C1-INH
(Berinert® P) [25-31]. No head-to-head trials comparing the
interventions were identified and due to significant het-
erogeneity between trials (differences in inclusion criteria
and assessing endpoints) a reliable indirect comparison
through a common comparator between trials was also
impossible [32]. Consequently, the analysis consisted of the
collated results obtained for direct comparisons with
placebo for all interventions of interest. The probability of
acute life-threatening attack of angioedema was additionally
assessed on the authority of clinical experts from the Depart-
ment of Clinical and Environmental Allergology, Jagiellon-
ian University Medical College. The treatment efficacy was
measured as: time to first improvement of symptoms and
the time to almost complete symptom relief and the prob-
ability of the intervention success. Due to the negative
impact of acute angioedema attacks on the life quality of
patients [33, 34], the decrease in life quality between and
during angioedema attacks was simulated. It was assumed
that life quality could be assessed from 0 (death) to 1 (per-
fect health). The Cost Effectiveness Analysis Registry Data-
base was searched and two publications including infor-
mation about life quality of patients with hereditary
angioedema (SF-36 scale [35], SF-12 scale [36]) were
found. However, no studies were found describing life qual-
ity during angioedema attacks, therefore decrease in life
quality was simulated on the basis of measurement in VAS
(Visual Analog Scale, which was used in clinical trials to mea-
sure symptom intensity of angioedema attacks). Symptom
intensity according to VAS ranges from 0 mm (no heredi-
tary angioedema), which meant no decrease in life quali-
ty, to 100 mm (extremely disabling) [23, 24] which meant
maximum worsening of life quality. Due to lack of appro-
priate data, the life quality between angioedema attacks
was set at 0.9 (average life quality in the general popula-
tion) [37]. Patients belonging to the cohorts that were not
actively treated could die from an acute life-threatening
angioedema attack (death risk was estimated at 30% [38,
39]) and according to the clinical trial results, mortality was
not considered among patients treated with active drugs
(Ruconest®, Berinert® P). Due to a relatively short time hori-
zon, mortality from causes other than acute attack of
angioedema was omitted. It should be also stressed that
lack of active treatment (equivalent to placebo in clinical
trials) is not a real (used in clinical practice) comparator for
assessed treatment options (conestat alfa, human C1-INH).
However, due to the heterogeneity of the clinical trials assess-
ing the efficacy and safety profile of the compared med-
ical products, a reliable direct comparison of costs and health
outcomes was not possible.
Costs
Medical resources used and cost categories were
indentified according to the data from the Department of
Clinical and Environmental Allergology, Jagiellonian University
Medical College. The cost was assessed in PLN and sub-
sequently calculated in EUR (based on the average
EUR/PLN exchange rate in 2011). The analysis included direct
healthcare costs from the perspective of healthcare pay-
er according to Polish AOTM guidelines [22]. Payments out
of the public healthcare budget as well as patients’ co-pay-
ments were included. It was assumed that Ruconest® (con-
estat alfa) would be financed from public funds within a new-
ly introduced therapeutic health program. The direct
medical costs were assessed on the basis of the literature
review and information provided by the National Health
Fund outlined in the regulations [40-42] and included: cost
of human C1-INH (at present, human C1-INH is financed by
the public payer within a target import procedure – as a life-
saving drug – and its cost amounts to EUR 0.78 for each
patient), cost of conestat alfa, cost of fresh frozen plasma
(currently financed by the public payer), cost of inpatient
and outpatient care during the administration of compared
treatment options (currently financed by the public payer),
cost of diagnostic procedures (currently financed by the pub-
lic payer). There were no direct non-medical costs includ-
ed in the analysis (e.g. transport costs, infrastructure
costs) due to lack of data. No influence of HAE on other
members of society than patients or on productivity was
found. Social perspective was not considered. Additional
or indirect lost productivity costs were ignored.
The price of conestat alfa used within the new intro-
duced therapeutic health program was based on informa -
tion from Swedish Orphan Biovitrum Sp. z o.o. Branch in
Poland, Value Added Tax and wholesale margin [43, 44]. 
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The wholesale price of conestat alfa was assessed at EUR
1,174.76 in 2012 (this price was used for simulation). The price
of human C1-INH from target import was assessed at EUR
932.52 and both these prices were tested in sensitivity analy-
sis. The consumption of compared treatment options
was estimated on the basis of Summaries of Product Char-
acteristics [8, 45] and the results of clinical trials [38, 39].
The average consumption of administered drugs during
a single, acute, life-threatening angioedema attack was esti-
mated at 1.83 vials of conestat alfa and 3.58 vials of human
C1-INH. In the framework of the therapeutic health program,
the Polish National Health Fund covers only cost of used
vial of conestat alfa while the rest is utilized and its cost
is covered by healthcare providers (hospitals, dispen-
saries). During target import of human C1-INH, the public
payer covers also the cost of the unused part of vial. Con-
sumption of assessed active substances was tested dur-
ing sensitivity analysis and the following parameters were
changed: average body weight (minimum and maximum),
percentage of patients involving the second drug admin-
istration (according to ranges of 95% confidence interval),
average number of used vials of human C1-INH (3-4). Fresh
frozen plasma is administered in special cases (lack of con-
estat alfa and human C1-INH) in actual clinical practice and
its cost (without administration cost) amounted to EUR
63.44. Inpatient and outpatient administration costs were
estimated on the basis of the questionnaire study and
amounted to PLN 348.5 (administration of human C1-INH)
and EUR 59.09 (in the case of conestat alfa administration).
When the new therapeutic health program is introduced,
the cost of diagnostic procedures would be included in the
cost of the program itself. It would be an annual lump sum
equal to product of the outpatient administration cost and
average number of acute life-threatening angioedema
attacks. Outpatient administration was assumed as the
cheapest option to be used in the diagnostic procedures
in acute life-threatening angioedema attacks. In the analy-
sis, total annual cost of diagnostic procedures was assessed
at EUR 85.37 per patient. Before starting up the treatment
with conestat alfa, examination against allergy for rabbits
should be conducted, however, their cost would be covered
by the producer.
Results
In the base case analysis with a one year’s perspective,
patients with HAE suffering from life-threatening angioede-
ma attacks gained on average 0.0261 quality adjusted life
years (QALY) when treated with Ruconest® (conestat alfa)
and 0.0262 QALY when treated with Berinert® P compared
with placebo (Table 2). One can conclude that the difference
in health outcomes between interventions were negligible.
The incremental costs of the therapy of a single acute
angioedema attack with conestat alfa amounted to app. EUR
419, app. EUR 755 per patient for human C1-INH treatment
in comparison with placebo, thus indicating that conestat
alfa is the cheapest option (Table 2). The median incremental
cost-utility ratios for assessed interventions compared with
placebo were as follows: EUR 15,226 per QALY (conestat alfa)
and EUR 27,786 per QALY (human C1 esterase inhibitor) –
Table 2. The results proved that Ruconest® (conestat alfa)
was cost-effective in comparison to no active treatment
(placebo) in the therapy of acute life-threatening angioede-
ma attacks in adults with HAE due to C1 esterase inhibitor
deficiency – median of incremental cost-utility ratios was
lower than the assumed threshold, EUR 24,279 per QALY.
On the basis of probabilistic analysis (which includes
1,000 simulations of the disease with the variability of the
model parameters presented in Table 1 within assumed
boundary values and their distribution), the likelihood of
cost utility (ICUR value below EUR 24,279 threshold) was
estimated at 41% for Berinert® P and 64% for Ruconest®.
The acceptability curves for each drug technology (Figure 2)
are depicting the percent of the simulations where each of
the treatments achieved the cost-utility level depending on
the assumed threshold meaning willingness-to-pay from
the healthcare payer’s perspective for an additional qual-
ity adjusted life year. It has been shown that the use of
Ruconest® financed within the newly introduced therapeutic
health program in place of the placebo associated with
potentially lower overall cost compared with Berinert® P.
Discussion
Results of the cost-utility analysis proved that the admin-
istration of Ruconest® (conestat alfa) within the therapeutic
Table 2. Results of the cost-utility analysis
Parameter Ruconest® Berinert® P
Quality-adjusted life years (QALY) in comparison to placebo (median)* 0.0261 QALY 0.0262 QALY
Total incremental costs in comparison to placebo (median)** EUR 419.27# EUR 754.63#
(PLN 1,719) (PLN 3,094)
Incremental Cost-Utility Ratio (ICUR) in comparison to placebo (median) EUR 15,225.61# per QALY EUR 27,786.34# per QALY
(PLN 62,425 per QALY) (PLN 113,924.00 per QALY)
Percentage of simulations where treatment option was cost-effective 64% 41%
in comparison to placebo
*p = 0.346, medians were not significantly different, **p < 0.0001, medians were significantly different; #assuming that EUR 1 = PLN 4.10
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health program would create a profitable treatment option
from a payer’s perspective (National Health Fund and
patient). The administration of Ruconest® (conestat alfa)
was associated with higher probability of cost-utility. Ad -
ditionally, the positive decision about financing of Rucon-
est® (conestat alfa) within the therapeutic health program
in the assessed medical indication has other advantages.
Introduction of the therapeutic health program would assure
permanent access (in the case of a direct life threat
caused by an acute angioedema attack) to effective treat-
ment options for patients with HAE. According to Polish and
international guidelines, Ruconest® (conestat alfa) should
be administered whenever there is a significant therapeutic
indication [11-13, 26-46].
Surely, the absence of direct or indirect comparison be -
tween the treatment options is a limitation of the analy-
sis, but it was impossible to perform such collation due to
the lack of appropriate clinical data (no head-to-head tri-
als and significant heterogeneity between placebo controlled
trials). It should be stressed that lack of the active treatment
(equivalent to placebo in clinical trials) is not a real (used in
clinical practice) comparator for assessed treatment op tions
(conestat alfa, human C1-INH). 
It might appear that the one-year time horizon was
assumed arbitrarily. Though, the choice is justified because
the administration of Ruconest® (conestat alfa) and Be -
rinert® P (human C1-INH) prevented death to the same
extent, therefore considering costs and health outcomes
(quality-adjusted life years) in a time horizon longer than
one year could solely multiply differences observed in one
year. The choice of 1-year horizon decreased incremental
changes between Ruconest® and the comparator which was
a conservative assumption when taking into account
higher clinical efficacy of Ruconest®. 
There was no possibility to assess precisely costs of diag-
nostic procedures settled within the potentially intro-
duced therapeutic health program. Estimation of these costs
was based on the assumption that they would be introduced
as an annual lump sum equal to the product of the aver-
age number of acute, life-threatening attacks and in-hos-
pital administration cost. Still, testing of these assumptions
within sensitivity analysis (cost summary) did not signifi-
cantly influence the assumed costs.
Moreover, the life quality during an angioedema attack
was assessed as a result of modeling (based on severity of
the symptoms) and the life quality in the period between
angioedema attacks was assumed arbitrarily at a level of 0.9
(due to lack of relevant data) – so the quality of life in the health
states included are still a rough estimate of the reality. 
The sensitivity analysis proved assumptions from ba -
sic analysis and showed that the use of Ruconest® with-
in the newly introduced therapeutic health program is asso-
ciated with a potentially lower cost from the perspective
of the payer than the use of Berinert® P.
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